Current Edition

COVID-19

Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst

After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars …

Continue Reading →
Asia

Using sumo ads, Moderna makes a heavy marketing push in Japan to rebuild trust in its COVID-19 vaccine

When some Moderna COVID-19 vaccine vials were found to be contaminated with metallic shards last year in Japan, the company suffered a reputation crisis in …

Continue Reading →
children

Moderna seeks FDA nod for COVID vaccine in children under 6, starts delayed filing for older kids

Moderna has new data backing the use of its COVID-19 vaccine Spikevax at a low dose in the youngest children under the age of 6, …

Continue Reading →
BioNTech

BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report

Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come. Germany will pay …

Continue Reading →
biotech

Novavax finally submits its COVID-19 vaccine to the FDA. Is it too late?

It’s finally here: After a series of delays in the lead-up to Novavax’s COVID-19 vaccine filing with the FDA, the biotech has completed its emergency …

Continue Reading →
DNA

DNA vaccine spurs antibodies against a common Parkinson’s target in mice

The neuronal protein alpha-synuclein has long been a target for Parkinson’s disease research, but it has delivered mixed results across multiple different therapeutics. Now, a …

Continue Reading →
COVID-19

US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes

With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. …

Continue Reading →
COVID-19

JPM 2022: Pfizer bumps Paxlovid production estimate to 120M for this year while also looking to add more capacity

Developing a COVID-19 vaccine at breakneck speed was a monumental achievement for Pfizer and BioNTech. The accompanying manufacturing effort is just as onerous. Similarly, as …

Continue Reading →
BioNTech

Pfizer, BioNTech say omicron partially evades its COVID vaccine but booster can restore protection

The COVID-19 vaccine produced by Pfizer and BioNTech, Comirnaty, provides less protection against the omicron variant than it did against wild-type COVID and other variants, …

Continue Reading →
BioNTech

As BioNTech raises expected COVID-19 vaccine sales to $19.6B, CEO stumps for wider booster use

Like its partner on its COVID-19 vaccine, BioNTech keeps upping its estimate for 2021 vaccine revenue. Last week, Pfizer jacked up its annual guidance on …

Continue Reading →